Home — Blog — R&D Tax Credits: Fueling Innovation in Technology & Life Sciences

R&D Tax Credits: Fueling Innovation in Technology & Life Sciences

July 9, 2026

Article

3 minute read

R&D Tax Credits: Fueling Innovation in Technology & Life Sciences

Executive Summary

Research and development (R&D) tax credits, also known the research and experimental (R&E) credit, are more than a tax benefit. They are a strategic engine for growth and innovation. For companies in the technology and life sciences sectors, these incentives can unlock meaningful cash flow, support reinvestment, and accelerate development cycles.

From software and artificial intelligence to drug discovery and clinical trials, a broad spectrum of activities may qualify. Recent legislative changes, including the One Big Beautiful Bill Act (OBBBA), have further enhanced these opportunities through immediate expensing and expanded benefits. However, capturing full value requires a thoughtful, well-documented approach that aligns technical activities with qualifying costs, especially within today’s complex development environments, including cloud computing and outsourced research.

From Code to Cure: Driving Innovation Forward

Technology and life sciences companies are redefining what’s possible, such as building scalable platforms, advancing AI capabilities, and developing life-saving therapies and medical devices.

Whether it’s designing next-generation software architectures, training machine learning models, engineering biologics, or optimizing manufacturing processes, these industries live at the cutting edge. Not surprisingly, they also represent some of the largest beneficiaries of the R&D tax credit, transforming innovation into tangible financial value.

Make Innovation Pay: Turn Effort into Impact

The R&D tax credit delivers powerful, multi-layered benefits, such as:

  • Dollar-for-dollar reduction in federal income tax
  • AMT offset opportunities for eligible taxpayers
  • Payroll tax offsets for qualified startups
  • Carryforward benefits of up to 20 years
  • State-level incentives that further amplify savings

In short: you innovate, you invest, you benefit.

Legislative Momentum: A New Era for R&D

The OBBBA brings a significant shift in tax treatment, including:

  • Immediate expensing of domestic R&D costs for tax years beginning after Dec. 31, 2024
  • Continued 15-year amortization for foreign R&D

This results in improved cash flow, faster cost recovery, and greater flexibility for companies investing heavily in innovation.

The Four-Part Test: Qualifying with Confidence

To qualify, activities must meet four core criteria:

  • Permitted Purpose – Driving a new or improved product, process, or technology
  • Technological in Nature – Grounded in hard sciences such as engineering, biology, chemistry or computer science
  • Elimination of Uncertainty – Addressing technical challenges or unknowns
  • Process of Experimentation – Evaluating alternatives through testing or modeling

R&D in Action: Technology Sector

Examples of qualifying work include:

  • Developing software platforms and SaaS solutions
  • Designing AI/ML algorithms and training models
  • Building scalable cloud infrastructure
  • Enhancing cybersecurity and encryption capabilities

R&D in Action: Life Sciences Sector

Examples of qualifying work include:

  • Drug discovery and formulation development
  • Clinical trial design and execution
  • Medical device innovation
  • Bioprocess development and manufacturing scale-up

Key Considerations: Getting It Right

  • Cloud computing costs tied to development activities may qualify, while general SaaS expenses typically do not
  • Contract research and internal-use software require careful analysis and proper treatment
  • Alignment is critical — linking activities, costs, and documentation is key to maximizing the credit

Conclusion: Turn Innovation into a Competitive Advantage

Innovation alone is not enough. Capturing its value drives sustainable growth.

Technology and life sciences companies that take a strategic approach to R&D tax credits can unlock meaningful cash flow, reinvest in innovation, and strengthen their competitive position. By combining federal credits, favorable treatment of research expenditures under recent legislation, and state incentives, organizations can maximize returns on their most valuable asset — innovation.

Ready to turn your innovation into measurable value? Connect with CBIZ to explore how a strategic R&D tax credit approach can help you maximize savings and accelerate growth.

Author
CBIZ Technology

CBIZ Technology is the premier technology solutions provider for small and midsize organizations. With over 50 years of experience in delivering innovative technology solutions, we are leaders in Managed Cloud, Accounting/ERP Software, Managed IT and Cybersecurity. We offer holistic technology solutions to enable our clients to scale, protect, and streamline their organizations.

Stay in the loop

Subscribe with your email address to stay updated on industry news, product releases, case studies, and more!

This field is for validation purposes and should be left unchanged.

CBIZ Technology
Corporate Headquarters

68 South Service Road, Suite 300 Melville, NY 11747
877-454-0039

Get Social

Join the conversation and connect with us on our social media channels.

Online Support

For existing CBIZ Technology customers.

“Grant Thornton” refers to the brand name under which the Grant Thornton member firms provide services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton LLP and Grant Thornton Advisors LLC operate as the US member firm of Grant Thornton International Limited (GTI). GTI is a non-practicing, international coordinating entity organized as a private company limited by guarantee incorporated in England and Wales. GTI and the member firms are not a worldwide partnership. GTI and each member firm are separate legal entities. Services are delivered by the member firms; GTI does not provide services to clients. GTI and its member firms are not agents of, and do not obligate, one another and are not liable for one another’s acts or omissions. “Grant Thornton Advisors” refers to a multinational platform, which is a group of firms that individually are part of the Grant Thornton network that connects priority markets and operates with aligned standards, technology and delivery expectations. Platform firms operate as separate legal entities.


CBIZ Technology, Inc. ©2026 • All Rights Reserved.